Key Details
- Inspection Authority: Brazilian Health Regulatory Agency (ANVISA)
- Facility Inspected: API manufacturing facility in Limbasi
- Inspection Period: June 8 to June 12, 2026 (5 days)
- Outcome: Successful completion of inspection
Strategic Significance
The company states that this achievement:
- Marks a significant milestone in Concord Biotech's global growth journey
- Reinforces commitment to the highest standards of quality and regulatory excellence
- Strengthens global manufacturing and regulatory footprint
- Advances international expansion strategy by enhancing access to the Brazilian pharmaceutical market (described as "one of the world's largest pharmaceutical markets")
- Broadens the reach of the company's high-quality APIs across key global geographies